dupilumab atopic dermatitis
Selected indexed studies
- Dupilumab for treatment of atopic dermatitis. (Expert Rev Clin Pharmacol, 2018) [PMID:29557246]
- Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. (J Allergy Clin Immunol, 2019) [PMID:30194992]
- Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: A retrospective cohort study. (J Am Acad Dermatol, 2024) [PMID:38588818]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Dupilumab for treatment of atopic dermatitis. (2018) pubmed
- Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. (2019) pubmed
- Abrocitinib versus dupilumab: Impact on skin barrier function and proteomics in atopic dermatitis. (2025) pubmed
- Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: A retrospective cohort study. (2024) pubmed
- Treatment With Dupilumab in Patients With Atopic Dermatitis: Systematic Review and Meta-Analysis. (2022) pubmed
- Reduced atopic march risk in pediatric atopic dermatitis patients prescribed dupilumab versus conventional immunomodulatory therapy: A population-based cohort study. (2024) pubmed
- A Review of Dupilumab in the Treatment of Atopic Dermatitis in Infants and Children. (2024) pubmed
- Management of inadequate response and adverse effects to dupilumab in atopic dermatitis. (2022) pubmed
- Attenuating the atopic march: Meta-analysis of the dupilumab atopic dermatitis database for incident allergic events. (2023) pubmed
- AP2M1 as the potential biomarker for prediction of the response of atopic dermatitis to Dupilumab therapy: Multi-omics analysis and evidence. (2025) pubmed